Welcome.. If you stumble across this board, welcome. Be

New Post Public Reply Private Reply Replies (0) Message Board
joey68
584
Welcome..

If you stumble across this board, welcome. Be sure to click the "Show Board Information" at the top to read the disclaimer.


Understand this:

This is NOT investment advice.

There is a VERY HIGH degree of RISK involved in trading and INVESTING. Only invest what you can afford to lose.

EVERYONE investing should speak to an investment professional PRIOR to investing.

Have you?
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 3

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
CRESYN Opens Model Residence: A Peek at City Living

Updated Category News Views 2

CRESYN: Urban Elegance Hits Long Island City Who doesn't want to peek under the hood when a flashy new ride rolls into town? CRESYN's newly unveiled model residence in Long Island City is just that—an invitation to get up close and personal with what modern urban living can be. Forget the blueprints and glossy renderings. This place is the real deal, giving you that...

Continue Reading
Clark Pacific's Arizona Plant to Triple Output by 2027

Updated Category News Views 2

Clark Pacific's Bold Expansion You've got to admire the guts it takes to break new ground, both literally and figuratively. That's exactly what Clark Pacific is doing by launching a spanking new facility in Coolidge, Arizona. It ain't just any plant, either. We're talking about a colossal 110-acre site that'll eventually boost the company's production capacity threefold....

Continue Reading
Carestream's Enhanced DRX-LC: Imaging Game Changer

Updated Category News Views 1

Rethinking Long-Length Imaging with Carestream The medical imaging sector just got a shot in the arm with Carestream Healthcare International's latest leap in technology. The DRX?LC Detector is not just a fancy update — it's a full-on revolution for long?length imaging. Forget the old days of piecing multiple exposures together, because this innovation simplifies...

Continue Reading
Terrabis Revolutionizes Illinois with Dual-Window Dispensary

Updated Category News Views 0

Terrabis Unveils a Speedier Cannabis Experience What do you do when the world is demanding faster service? You innovate. That’s precisely what Terrabis has done by unveiling Illinois' first dual-window drive-thru dispensary in Grayville. Situated just off I-64, this facility isn't just offering a new way of doing things; it's setting the stage for what might very well...

Continue Reading
DELIVAN Unveils Electric Vans and Expansion in Europe

Updated Category News Views 2

DELIVAN Charging Forward with All-Electric Vans Mark the calendar—September 4, 2026, marked a big day for DELIVAN. The company's foray into the European market is getting serious, splashed across IAA Transportation in all its glory. Unveiling two fresh all-electric production vans, DELIVAN's not just tiptoeing onto the scene; it's diving headfirst into Europe's buzzing...

Continue Reading
Connected Retail Security: Rising Risks and Fragmented Roles

Updated Category News Views 4

Cyber Threats in the Connected Retail Landscape The retail world isn't what it used to be. Walk into a store today, and you're greeted not just by products but a web of interconnected systems screaming for attention. Sure, you've got your old-school POS systems humming along, but they're just one brittle cog in a rattling machine of IoT devices, cloud platforms, and...

Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Updated Category News Views 1

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Continue Reading
Tetragon Completes $50M Tender Offer; Shares Prorated

Updated Category News Views 0

Unpacking Tetragon’s $50 Million Dutch Auction Move If you comb through the smoke-filled corridors of finance, you'll find the name Tetragon Financial Group pacing the latest tender offer rounds. They danced their way through a $50 million 'modified Dutch auction,' snapping up non-voting shares with a kind of ruthless efficiency that only seasoned market players can...

Continue Reading
PROCEPT Faces Legal Storm Over Sales Practices Missteps

Updated Category News Views 1

Investors Take Aim: A Legal Showdown on the Horizon There's a brewing storm over at PROCEPT BioRobotics—ticker NASDAQ:PRCT if you're tracking. These folks are knee-deep in a securities class action lawsuit from investors who’ve taken a financial wallop. The lawsuits are triggered by allegations of shady sales techniques that artificially bumped up their unit sales...

Continue Reading

Top 5 Most Recently Viewed Articles

Amalgamated Financial Corp. Announces Dividend and Growth Strategy

Updated Category News Views 180

Amalgamated Financial Corp. Declares Regular Quarterly Dividend Amalgamated Financial Corp., known for its commitment to financial excellence, has recently made an important announcement regarding its dividend policy. The Board of Directors has decided to declare a regular dividend of $0.14 per share for its common stockholders. This payment is a gesture of appreciation...

Continue Reading
Analyzing KBRA's Latest Research on Retail Sales Trends

Updated Category News Views 89

Insights into KBRA's Retail Sales Research KBRA has recently released significant research focusing on retail sales trends for August. Their findings reveal a small increase in retail sales, but they also indicate a clear decline in consumer resilience. This study comes at a time when inflation rates are dropping and the job market, while still strong, is starting to show...

Continue Reading
Biogen's Strategic Outlook: Challenges and Opportunities Ahead

Updated Category News Views 2005

Biogen's Current Market Position and Recent Developments Biogen Inc. (NASDAQ: BIIB), a prominent player in the biotechnology sector with a focus on neurological treatments, is navigating a pivotal moment. The company is poised to launch its much-anticipated Alzheimer's drug, Leqembi, while addressing recent challenges within its pipeline. This analysis delves into...

Continue Reading
Morgan Stanley Revises Suzlon Energy Rating Amid Market Shifts

Updated Category News Views 236

Morgan Stanley revised its stance on Suzlon Energy (SUEL:IN) back in mid-2024, downgrading its rating from Overweight to Equalweight. This shift came alongside an increase in the price target from INR73.00 to INR88.00, suggesting a strategic pivot after a jaw-dropping 106% spike in the company’s share price over six months. Performance Breakdown: Is It Justified? Now,...

Continue Reading
Copenhagen Infrastructure Acquires Key Australian Wind Project

Updated Category News Views 23

A Pivotal Move in Renewable Energy Investment Copenhagen Infrastructure Partners (CIP) isn’t just dabbling in Australia's energy sector—they're going full throttle with the acquisition of the Gawara Baya project. This hybrid onshore wind and battery energy storage system (BESS) is a serious chunk of infrastructure designed to shake up North Queensland's power...

Continue Reading